Matches in SemOpenAlex for { <https://semopenalex.org/work/W2811203629> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2811203629 endingPage "102" @default.
- W2811203629 startingPage "102" @default.
- W2811203629 abstract "Background: Naringin, pharmaceutically active flavonoid, rapidly metabolizes in liver into naringenin. Both naringin and naringenin have significant biological activity and less toxicity. Objective: In the present study, in silico molecular interactions of naringin and its metabolite naringenin have been evaluated against different human liver fibrosis proteins. Materials and Methods: The major human therapeutic protein targets such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor-2 (VEGFR-2), fibroblast growth factor receptor-1 (FGFR1), Kelch-like ECH-associated protein-1 (Kaep1), transforming growth factor beta receptor I (TGFBR-1), angiotensin II receptor type-1 (Angio-II-Type-1), Janus kinase-2 (JAK-2), Zeta-chain-associated protein kinase-70 (ZAP-70) have been selected for the docking studies. This computational study was performed using Schrodinger Suite Maestro 10.3 Glide software 2015. Results: The studies demonstrated comparable binding affinities of naringin and naringenin with human therapeutic protein targets such as JAK-2, ZAP-70 Kinase, Angio-II-Type 1, TGFBR1, Kaep1, EGFR, VEGFR-2, and FGFR1 when compared to their respective standard drugs such as gefitinib, regorafenib, dovitinib, bardoxolone methyl, SB-431542, olmesartan, and ruxolitinib. Naringin showed better glide score ranging from −8.5 to −13.3 kcal/mol whereas its metabolite Naringenin also showed comparable glide score ranging from −5.4 to −9.3 kcal/mol. The binding of target proteins with respective standard drugs showed −2.2 to −10.12 kcal/mol. Conclusion: The observed in silico human protein interactions of naringin and its metabolite naringenin could be exploited for the anti-liver fibrosis therapy. The results derived from this pioneering virtual study may advance further mechanistic in vitro and preclinical in vivo studies. Abbreviations used: Jak-2: Janus kinase-2, ZAP-70: Zeta-chain-associated protein kinase-70, Angio-II-type-1: Angiotensin II receptor type-1, TGFBR1: Transforming growth factor beta receptor I, Kaep1: Kelch-like ECH-associated protein-1, EGFR: Epidermal growth factor receptor, VEGFR-2: Vascular endothelial growth factor receptor-2, FGFR1 kinase: Fibroblast growth factor receptor-1." @default.
- W2811203629 created "2018-07-10" @default.
- W2811203629 creator A5014925776 @default.
- W2811203629 creator A5019446709 @default.
- W2811203629 creator A5074827406 @default.
- W2811203629 date "2018-01-01" @default.
- W2811203629 modified "2023-09-27" @default.
- W2811203629 title "Molecular interaction of naringin and its metabolite naringenin to human liver fibrosis proteins: An In Silico approach" @default.
- W2811203629 cites W2051239278 @default.
- W2811203629 doi "https://doi.org/10.4103/pm.pm_453_17" @default.
- W2811203629 hasPublicationYear "2018" @default.
- W2811203629 type Work @default.
- W2811203629 sameAs 2811203629 @default.
- W2811203629 citedByCount "0" @default.
- W2811203629 crossrefType "journal-article" @default.
- W2811203629 hasAuthorship W2811203629A5014925776 @default.
- W2811203629 hasAuthorship W2811203629A5019446709 @default.
- W2811203629 hasAuthorship W2811203629A5074827406 @default.
- W2811203629 hasConcept C104317684 @default.
- W2811203629 hasConcept C142724271 @default.
- W2811203629 hasConcept C181199279 @default.
- W2811203629 hasConcept C185592680 @default.
- W2811203629 hasConcept C2775905019 @default.
- W2811203629 hasConcept C2776418720 @default.
- W2811203629 hasConcept C2776848411 @default.
- W2811203629 hasConcept C2777335409 @default.
- W2811203629 hasConcept C2777477808 @default.
- W2811203629 hasConcept C2778004101 @default.
- W2811203629 hasConcept C2779054382 @default.
- W2811203629 hasConcept C2780559512 @default.
- W2811203629 hasConcept C2994217296 @default.
- W2811203629 hasConcept C2994400308 @default.
- W2811203629 hasConcept C43617362 @default.
- W2811203629 hasConcept C55493867 @default.
- W2811203629 hasConcept C70721500 @default.
- W2811203629 hasConcept C71924100 @default.
- W2811203629 hasConcept C86803240 @default.
- W2811203629 hasConcept C98274493 @default.
- W2811203629 hasConceptScore W2811203629C104317684 @default.
- W2811203629 hasConceptScore W2811203629C142724271 @default.
- W2811203629 hasConceptScore W2811203629C181199279 @default.
- W2811203629 hasConceptScore W2811203629C185592680 @default.
- W2811203629 hasConceptScore W2811203629C2775905019 @default.
- W2811203629 hasConceptScore W2811203629C2776418720 @default.
- W2811203629 hasConceptScore W2811203629C2776848411 @default.
- W2811203629 hasConceptScore W2811203629C2777335409 @default.
- W2811203629 hasConceptScore W2811203629C2777477808 @default.
- W2811203629 hasConceptScore W2811203629C2778004101 @default.
- W2811203629 hasConceptScore W2811203629C2779054382 @default.
- W2811203629 hasConceptScore W2811203629C2780559512 @default.
- W2811203629 hasConceptScore W2811203629C2994217296 @default.
- W2811203629 hasConceptScore W2811203629C2994400308 @default.
- W2811203629 hasConceptScore W2811203629C43617362 @default.
- W2811203629 hasConceptScore W2811203629C55493867 @default.
- W2811203629 hasConceptScore W2811203629C70721500 @default.
- W2811203629 hasConceptScore W2811203629C71924100 @default.
- W2811203629 hasConceptScore W2811203629C86803240 @default.
- W2811203629 hasConceptScore W2811203629C98274493 @default.
- W2811203629 hasIssue "55" @default.
- W2811203629 hasLocation W28112036291 @default.
- W2811203629 hasOpenAccess W2811203629 @default.
- W2811203629 hasPrimaryLocation W28112036291 @default.
- W2811203629 hasRelatedWork W1509926796 @default.
- W2811203629 hasRelatedWork W2004256497 @default.
- W2811203629 hasRelatedWork W2012068646 @default.
- W2811203629 hasRelatedWork W2030065489 @default.
- W2811203629 hasRelatedWork W2049416638 @default.
- W2811203629 hasRelatedWork W2057267277 @default.
- W2811203629 hasRelatedWork W2125027675 @default.
- W2811203629 hasRelatedWork W27741334 @default.
- W2811203629 hasRelatedWork W2811203629 @default.
- W2811203629 hasRelatedWork W3013505907 @default.
- W2811203629 hasVolume "14" @default.
- W2811203629 isParatext "false" @default.
- W2811203629 isRetracted "false" @default.
- W2811203629 magId "2811203629" @default.
- W2811203629 workType "article" @default.